RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Type C Meeting TimingsBracelet-1 demonstrated that pelareorep is effective as a monotherapy when coupled with paclitaxel veresus the control arm of paclitaxel alone.
If you Quentin30 were in industry and had any relevant industry experience, which doesn't appear to be the case,you would know how this is relevant to pelareorep when combined with other immuntrherapeutics and small molecules agents. Bracelet-1 determined that pelareorep is the active agent - not the chemotherapy nor the ICI (avelumab). Goblet-1 is showing that pelareoerep in combination with an Fc inactivated ICI is synergistic in multiple cancers, aand in potentially multiple combinations of cancer fighting possibilities.